Clinical trial
Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be…
NCT00482625 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00482625 |
|---|---|
| Title | Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery |
| Official title | Phase IIA Trial Testing Erlotinib as an Intervention Against Intraductal Pancreatic Mucinous Neoplasms |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Intraductal Papillary Mucinous Neoplasm of the Pancreas, Recurrent Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer |
| Intervention type | Drug, Genetic, Other, Procedure |
| Interventions | erlotinib hydrochloride, conventional surgery, immunohistochemistry staining method, protein expression analysis, biopsy, pharmacological study, laboratory biomarker analysis |
| Enrollment | 6 |
| Start date | Jun 1, 2007 |
| Primary completion | Feb 1, 2010 |
| Completion | Sep 1, 2013 |
| First posted | Jun 5, 2007 |
| Last update posted | Oct 16, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: